Clinical Trial Update: An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the efficacy of the osmotic-release methylphenidate formulation in Attention-Deficit/Hyperactivity Disorder; results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• OROS-Methylphenidate (methylphenidate, osmotic release formulation)

Snippet

Sponsor: Janssen Korea, Ltd., Korea | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 4 | Status: COMPLETED | Results posted: 2013-07-31